Article Sidebar
Main Article Content
IREB2 Knockdown Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by TLR4/NF-κB Signaling Inactivation
Main Article Content
Abstract
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases and is characterized by extensive deposition of fat in hepatocytes. This study aims to elucidate iron responsive element binding protein 2’s (IREB2) role in highfat diet (HFD)-induced NAFLD and the regulatory mechanisms of the TLR4/NF-κB cascade.
Materials and Methods: Male rats were fed an HFD to induce the NAFLD in vivo model. Changes in body weight and liver tissue weight were measured. Liver tissue damage and hepatic steatosis were monitored by hematoxylin–eosin staining in rats. Fat droplet size of rat liver tissue was detected by oil red O staining kit to evaluate fat deposition. Total cholesterol (TC), triglycerides (TG), alanine transaminase (ALT), Aspartate transaminase (AST), fatty acid synthase (FAS, and PPARα were detected by enzyme-linked immunosorbent assay (ELISA) kit and western blot. Interleukin-1-beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were detected by ELISA. Finally, glucose tolerance and insulin sensitivity were measured by glucose analyzer.
Results: IREB2 was highly expressed in the liver tissue of NAFLD rats. The body weight and liver tissue weight of rats with knockdown of IREB2 were lower than those fed HFD, and the liver tissue was severely damaged, serum ALT/AST activity, glucose, TG, and TC levels were increased. In addition, overexpressing IREB2 increased IL-1β, IL-6, and TNF-α, promoting HFD-induced metabolic disorders, hepatic steatosis, and inflammation. Knocking down IREB2 had the opposite effect. Blocking the TLR4/NF-κB cascade reversed the promoting effect of IREB2 on steatosis and inflammatory response.
Conclusion: NAFLD treatment and prevention could benefit from IREB2, which may be closely related to TLR4/NF-κB signaling in lipid metabolism and glucose tolerance.
Cite this article as: Hu Y, Zhang S, Jiang Q, Chen T, Luo J, Jiang Y. IREB2 knockdown alleviates high-fat diet-induced nonalcoholic fatty liver disease by TLR4/NF-κB signaling inactivation. Turk J Gastroenterol. Published online February 4, 2025. doi 10.5152/ tjg.2025.24054.
Article Details
References
1. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-2682. [CrossRef]
2. Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314-322. [CrossRef]
3. Ross AP, Darling JN, Parent MB. Excess intake of fat and sugar potentiates epinephrine-induced hyperglycemia in male rats. J Diabetes Complications. 2015;29(3):329-337. [CrossRef]
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231. [CrossRef]
5. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(suppl 1):S104-S112. [CrossRef]
6. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41(1):66-117. [CrossRef]
7. Ghareghani P, Shanaki M, Ahmadi S, et al. Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice. Obes Res Clin Pract. 2018;12(suppl 2):80-89. [CrossRef]
8. Keating SE, Hackett DA, Parker HM, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63(1):174-182. [CrossRef]
9. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55(6):1738-1745. [CrossRef]
10. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-414. [CrossRef]
11. Coon KD, Siegel AM, Yee SJ, et al. Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer’s disease. J Alzheimers Dis. 2006;9(3):225-233. [CrossRef]
12. DeMeo DL, Mariani T, Bhattacharya S, et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet. 2009;85(4):493-502. [CrossRef]
13. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3(6):535-537. [CrossRef]
14. Li X, Wu L, Tian X, et al. miR-29a-3p in exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells alleviates steatotic liver ischemia-reperfusion injury in rats by suppressing ferroptosis via iron responsive element binding protein 2. Oxid Med Cell Longev. 2022;2022:6520789. [CrossRef]
15. Kiziltas S, Ata P, Colak Y, et al. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab Syndr Relat Disord. 2014;12(3):165-170. [CrossRef]
16. Pietilä TE, Veckman V, Lehtonen A, Lin R, Hiscott J, Julkunen I. Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J Immunol. 2007;178(1):253-261. [CrossRef]
17. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov. 2002;1(10):797-807. [CrossRef]
18. Ma J, Chadban SJ, Zhao CY, et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One. 2014;9(5):e97985. [CrossRef]
19. Yokoyama T, Komori A, Nakamura M, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int. 2006;26(4):467-476. [CrossRef]
20. Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res. 2018;32(5):389-400. [CrossRef]
21. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. [CrossRef]
22. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48(1):1-26. [CrossRef]
23. Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019;10(6):449. [CrossRef]
24. Yamada N, Karasawa T, Wakiya T, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis. Am J Transplant. 2020;20(6):1606-1618. [CrossRef]
25. Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021;75(3):506-513. [CrossRef]
26. Tacchini L, Fusar Poli D, Bernelli-Zazzera A, Cairo G. Transferrin receptor gene expression and transferrin-bound iron uptake are increased during postischemic rat liver reperfusion. Hepatology. 2002;36(1):103-111. [CrossRef]
27. Ganz M, Csak T, Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol. 2014;20(26):8525-8534. [CrossRef]
28. Kamada Y, Kiso S, Yoshida Y, et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1031-G1043. [CrossRef]
29. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis. 2010;28(1):247-254. [CrossRef]
30. Alves CC, Waitzberg DL, de Andrade LS, et al. Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver. Front Microbiol. 2017;8:2010. [CrossRef]
31. Sheng D, Zhao S, Gao L, et al. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling. Cell Biosci. 2019;9:77. [CrossRef]
32. Su Q, Baker C, Christian P, et al. Hepatic mitochondrial and ER stress induced by defective PPARα signaling in the pathogenesis of hepatic steatosis. Am J Physiol Endocrinol Metab. 2014;306(11):E1264-E1273. [CrossRef]
33. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S53-S55. [CrossRef]
34. Zhou S, You H, Qiu S, et al. A new perspective on NAFLD: focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother. 2022;154:113577. [CrossRef]
35. Smith EL, Somma D, Kerrigan D, et al. The regulation of sequence specific NF-κB DNA binding and transcription by IKKβ phosphorylation of NF-κB p50 at serine 80. Nucleic Acids Res. 2019;47(21):11151-11163. [CrossRef]
36. Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(8):570-579. [CrossRef]
37. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-788. [CrossRef]